Sort by

Send to

Choose Destination

Search results

Items: 5


Data-Driven Construction of Antitumor Agents with Controlled Polypharmacology.

Da C, Zhang D, Stashko M, Vasileiadi E, Parker RE, Minson KA, Huey MG, Huelse JM, Hunter D, Gilbert TSK, Norris-Drouin J, Miley M, Herring LE, Graves LM, DeRyckere D, Earp HS, Graham DK, Frye SV, Wang X, Kireev D.

J Am Chem Soc. 2019 Oct 2;141(39):15700-15709. doi: 10.1021/jacs.9b08660. Epub 2019 Sep 20.


MERTK inhibition alters the PD-1 axis and promotes anti-leukemia immunity.

Lee-Sherick AB, Jacobsen KM, Henry CJ, Huey MG, Parker RE, Page LS, Hill AA, Wang X, Frye SV, Earp HS, Jordan CT, DeRyckere D, Graham DK.

JCI Insight. 2018 Nov 2;3(21). pii: 97941. doi: 10.1172/jci.insight.97941.


Targeting the TAM Receptors in Leukemia.

Huey MG, Minson KA, Earp HS, DeRyckere D, Graham DK.

Cancers (Basel). 2016 Nov 8;8(11). pii: E101. Review.


UNC2025, a MERTK Small-Molecule Inhibitor, Is Therapeutically Effective Alone and in Combination with Methotrexate in Leukemia Models.

DeRyckere D, Lee-Sherick AB, Huey MG, Hill AA, Tyner JW, Jacobsen KM, Page LS, Kirkpatrick GG, Eryildiz F, Montgomery SA, Zhang W, Wang X, Frye SV, Earp HS, Graham DK.

Clin Cancer Res. 2017 Mar 15;23(6):1481-1492. doi: 10.1158/1078-0432.CCR-16-1330. Epub 2016 Sep 20. Erratum in: Clin Cancer Res. 2017 Jul 15;23 (14 ):3971-3972.


The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia.

Minson KA, Smith CC, DeRyckere D, Libbrecht C, Lee-Sherick AB, Huey MG, Lasater EA, Kirkpatrick GD, Stashko MA, Zhang W, Jordan CT, Kireev D, Wang X, Frye SV, Earp HS, Shah NP, Graham DK.

JCI Insight. 2016 Mar;1(3):e85630. doi: 10.1172/jci.insight.85630.

Supplemental Content

Loading ...
Support Center